Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Avecho Biotechnology Limited ( (AU:AVE) ) just unveiled an announcement.
Avecho Biotechnology Limited announced its participation in the NWR Virtual Healthcare Conference, where it will discuss its recent licensing agreement with Sandoz AG for the Australian commercial rights to its CBD product. This agreement is pivotal for Avecho’s ongoing Phase III clinical trial of its CBD TPM soft-gel capsule, aimed at treating insomnia. The trial’s success could position Avecho as a leader in the Australian over-the-counter CBD market, especially given the regulatory changes allowing such sales without a prescription. The trial is designed to meet international regulatory standards and could significantly impact the company’s market presence if successful.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is a company that develops and commercializes innovative health products for humans and animals using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E and enhances the solubility and absorption of drugs and nutrients. The company’s lead product is a cannabidiol (CBD) TPM soft-gel capsule designed to improve CBD absorption, currently in Phase III clinical development for insomnia treatment.
Current Market Cap: A$22.19M
For an in-depth examination of AVE stock, go to TipRanks’ Stock Analysis page.